Arcturus Therapeutics Holdings Beheer
Beheer criteriumcontroles 2/4
De CEO Arcturus Therapeutics Holdings is Joe Payne, benoemd in Mar2013, heeft een ambtstermijn van 11.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.89M, bestaande uit 14.3% salaris en 85.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.46% van de aandelen van het bedrijf, ter waarde $ 23.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 5.8 jaar.
Belangrijke informatie
Joe Payne
Algemeen directeur
US$4.9m
Totale compensatie
| Percentage CEO-salaris | 14.3% |
| Dienstverband CEO | 11.7yrs |
| Eigendom CEO | 5.5% |
| Management gemiddelde ambtstermijn | 1.5yrs |
| Gemiddelde ambtstermijn bestuur | 5.8yrs |
Recente managementupdates
Recent updates
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Nov 14Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$107m |
| Dec 31 2023 | US$5m | US$698k | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$3m | US$425k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$26m |
| Jun 30 2018 | n/a | n/a | -US$25m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$449k | US$384k | -US$11m |
Compensatie versus markt: De totale vergoeding ($USD 4.89M ) Joe } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.24M ).
Compensatie versus inkomsten: De vergoeding van Joe is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Joe Payne (52 yo)
11.7yrs
Tenure
US$4,892,500
Compensatie
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 11.7yrs | US$4.89m | 5.46% $ 23.9m | |
| Founder | 11.8yrs | US$3.18m | 1.61% $ 7.0m | |
| CFO & Director | 6.3yrs | US$2.18m | 0.81% $ 3.6m | |
| Chief Legal Officer | 4.3yrs | US$2.10m | 0% $ 0 | |
| Vice President and Head of IR/PR & Marketing | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | 6.2yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Chief Development Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Chief Strategy Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Regulatory Officer | less than a year | geen gegevens | geen gegevens | |
| Controller | less than a year | geen gegevens | geen gegevens |
1.5yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ARCT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 11.7yrs | US$4.89m | 5.46% $ 23.9m | |
| CFO & Director | 5.2yrs | US$2.18m | 0.81% $ 3.6m | |
| Independent Chairman of the Board | 6.5yrs | US$328.00k | 0.36% $ 1.6m | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.2yrs | US$325.50k | 0.012% $ 50.6k | |
| Independent Director | 6.5yrs | US$330.50k | 0.048% $ 212.3k | |
| Independent Director | 6.5yrs | US$318.00k | 0.10% $ 453.9k | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 9.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 9yrs | geen gegevens | geen gegevens | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 2.7yrs | US$644.00k | geen gegevens | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens |
5.8yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ARCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).